Authors
Latest:
First-Line Treatment Selection in Lower-Risk MDSChris Benton, MD, provides an overview of first-line treatment options for patients with lower-risk myelodysplastic syndromes (LR-MDS).
Latest:
Next Steps for Investigation of Mobocertinib for EGFR Exon 20+ NSCLCDanny Nguyen, MD, discusses next steps for research of mobocertinib in patients with EGFR-positive non–small cell lung cancer.
Latest:
Mechanisms of Resistance to Noncovalent BTK Inhibitors in CLLSkye Montoya, discusses research that she was a part of on mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia.
Latest:
From Paper to Pixel: The Power of Digital Referral SystemsBy expediting referral processes, enhancing information quality, and boosting patient satisfaction, these systems are reshaping healthcare experiences for both providers and patients.
Latest:
Behind the Phase 1 Study of TAR-210 in FGFR-Altered NMIBCAntoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in patients with FGFR-altered high- and intermediate-risk non–muscle invasive bladder cancer.
Latest:
AON Creates More Community Oncology Practices Offering Personalized Care in ArizonaShana Wingo, MD, discusses the key goals of the partnership between community oncology practices and American Oncology Network.
Latest:
How AI Is Revolutionizing Oncology in Diagnosis, Treatment, and ResearchIn this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, discusses the transformative impact of artificial intelligence in oncology.
Latest:
Investigators Present Updated Results of the OpACIN Trial for MelanomaChristian U. Blank, MD, PhD, discusses the most recent data from the phase 1b OpACIN trial of ipilimumab and nivolumab in patients with macroscopic stage III melanoma.
Latest:
Updated Data From the TRIMM-2 Trial of Talquetamab and Daratumumab in RRMMBhagirathbhai R. Dholaria, MBBS, discusses updated findings from the TRIMM-2 trial of talquetamab and daratumumab for the treatment of relapsed/refractory multiple myeloma.
Latest:
Foran Goes Beyond the Basics of BPDCNIn this episode of Targeted Talks, James M. Foran, MD, discusses the presentation and diagnosis of blastic plasmacytoid dendritic cell neoplasm.
Latest:
Slomovitz on Tisotumab Vedotin's Promise for Cervical CancerBrian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.
Latest:
Can Just-in-Time Clinical Trials Reduce Disparities in Participation?Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.
Latest:
Predicting Responses to Immunotherapy in Patients With CancerNatalie I. U. Vokes, MD, discusses the future of predicting how patients will respond to treatment, especially immunotherapy, based on their genomic profile.
Latest:
Evaluating the Toxicity Profile of Parsaclisib in Mantle Cell LymphomaAmitkumar Mehta, MD, discusses the toxicity profile of parsaclisib in the phase 2 CITADEL-205 clinical trial of relapsed/refractory mantle cell lymphoma.
Latest:
Case 3: Role of Preoperative Endocrine Therapy in HR+ High-Risk Breast CancerHeather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.
Latest:
Innovative PET Imaging With Cu 64 Anti-CEA in Advanced Rectal CancerJeffrey Wong, MD, discusses findings on the use of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer presented at the 2024 American Society for Radiation Oncology Annual Meeting.
Latest:
Committee Helps Physician's Find Best Options for Patients Through NGSJennifer Marie Suga, MD, discusses how the results from next-generation sequencing tests are assessed to help physicians manage their patients in real-time.
Latest:
Exploring Outcomes From TROPION-Lung01 Presented at WCLC 2024Panelists discuss how the TROPION-Lung01 study results presented at World Conference on Lung Cancer 2024 shed light on overall survival outcomes in patients with lung cancer, with a particular focus on survival rates across different histological subtypes.
Latest:
Clinical Pearls for the Management of TCR MMAdriana Rossi, MD, provides clinical pearls on the management of triple-class refractory multiple myeloma.
Latest:
Sequencing Axatilimab and SafetyPanelists discuss where and when sequencing axatilimab becomes appropriate within the clinical setting, as well as safety precautions associated with the drug.
Latest:
Tolerability of Zilovertamab and Ibrutinib in Phase 1/2 Trial of MCLHun Ju Lee, MD, discusses the early results of the dose finding and safety study of zilovertamab plus ibrutinib for patients with mantle cell lymphoma as well as chronic lymphocytic leukemia and marginal zone lymphoma.
Latest:
ctDNA Points to the Future of Precision Medicine in Genitourinary CancersIn this feature article, key opinion leaders look at the burgeoning use of ctDNA to dictate treatment approaches for patients with bladder cancer.
Latest:
Adagrasib Outperforms Docetaxel for Pretreated KRAS G12C-Mutant Non–Small Cell Lung CancerAdagrasib demonstrated superior outcomes to docetaxel in patients with previously treated KRAS G12C-mutated non-small cell lung cancer, even among those with baseline brain metastases.
Latest:
Hematologists Should Consider What Comes Next for Patients With DLBCLElizabeth A. Brem, MD, discusses the familiarity of treatments among oncologists for patients with diffuse large B-cell lymphoma in a Case-Based Roundtable event.
Latest:
Mechanism-Driven Science Informs Novel Treatments in Soft Tissue SarcomaVarious combination strategies are being explored in soft tissue sarcomas in efforts to increase efficacy.
Latest:
Han Discusses the Promise of Ga 68 PSMA-11 and BgRTChunhui Han, PhD, discusses what biology-guided radiotherapy is and how it differs from traditional radiotherapy techniques.
Latest:
Examining ESR1 Alterations in HR-Positive Metastatic Breast CancerJamie Brett discusses the similarities and differences between ESR1 mutations and fusions and why they are grouped together.
Latest:
Advice for Clinicians on Treating Patients with Prostate CancerDr. Marc Matrana closes the discussion with considerations for clinicians on treating patients with prostate cancer.
